Silence Therapeutics Reports Steep Revenue Decline, Doubled Net Loss, and AstraZeneca Drops SLN312 Program
Summary
Silence Therapeutics announced significantly worse financial results for 2025, including a near-total collapse in collaboration revenue and a doubled net loss, alongside the termination of AstraZeneca's development of SLN312.
Key Events
-
Steep Revenue Decline
Collaboration revenue fell dramatically from $43.3 million in 2024 to $0.6 million for the full year ended December 31, 2025.
-
Net Loss Doubled
The company's net loss increased to $88.6 million for 2025, nearly doubling from $45.3 million in 2024.
-
AstraZeneca Terminates SLN312 Development
AstraZeneca notified Silence Therapeutics that it will not pursue further development of SLN312 beyond Phase 1, returning exclusive global rights to Silence.
-
Cash Position Decreased
Cash, cash equivalents, and short-term investments declined to $85.1 million as of December 31, 2025, from approximately $147.3 million in 2024.
Analysis
Silence Therapeutics' financial health has deteriorated significantly, with collaboration revenue plummeting and net losses nearly doubling year-over-year. This indicates a substantial cash burn and raises concerns about future funding and operational runway. The decision by AstraZeneca to cease development of SLN312 is a major setback for Silence's pipeline, as it loses a key partner for a clinical asset. While the accelerated timeline for Divesiran's Phase 2 results is a positive, it is heavily overshadowed by the severe financial performance and the loss of a significant partnership. Investors should monitor the company's cash runway and its strategy for SLN312 and other pipeline assets.
At the time of this filing, SLN was trading at $5.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $273M. The 52-week trading range was $1.97 to $7.78. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.